Trial · NCT03346668
Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia
NCT03346668, Early phase 1, Completed, University of Minnesota
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia. Trials, record NCT03346668. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03346668
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia
- NCT number
- NCT03346668
- Status
- Completed
- Phases
- Early phase 1
- Enrollment
- 5 participants, actual
- Lead sponsor
- University of Minnesota
- Conditions
- Scarring Alopecia, Frontal Fibrosing Alopecia, Lichen Planopilaris, Central Centrifugal Cicatricial Alopecia, Central Centrifugal Scarring Alopecia
- Interventions
- Topical gabapentin
- First posted
- 2017-11-17
- Last updated
- 2024-03-25
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Neurogenic inflammation-QOL | Change from Baseline to 14 weeks | Complete a QOL (Quality of Life) survey Scale= (Not relevant to Extremely Relevant) |
| Primary | Neurogenic inflammation-Short Form (36) Health Survey | Change from Baseline to 14 weeks | Complete Short Form (36) Health Survey Scale Scale=1-5 1 being the best and 5 being the worse |
| Primary | Neurogenic inflammation- Visual Analog pain Scale | Change from Baseline to 14 weeks | Visual Analog Pain scale Scale = 1-10 1 being the least pain and 10 being the worse pain |
| Secondary | Safety and efficacy of topical 6% gabapentin -Medication side Effects | Change from Baseline to 12 weeks | Subjects will have Medication side effects collected at day 0 and ending week 12 |
| Secondary | Safety and efficacy of topical 6% gabapentin -Blood levels | Change from Baseline to 12 weeks | Subjects will have blood levels measured at Day 0 and 12 weeks |
| Secondary | Safety and efficacy of topical 6% gabapentin -Adverse Events | Change from Baseline to 12 weeks | Subjects will have adverse events collected on day 0 and 12 weeks |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03346668
GET https://conductscience.org/api/trials/v1/NCT03346668/registered